The market capitalization of Lyell Immunopharma (traded under the ticker symbol LYEL) fluctuates continuously during active market trading hours based on real-time share price movements and total outstanding shares. Recent financial market trackers and valuation metrics place its total market value in the mid-hundreds of millions of dollars, generally hovering around the $350 million to $370 million range. As a small-cap clinical-stage biotechnology firm, its valuation shifts frequently in response to clinical trial updates, regulatory announcements, cash runway disclosures, and broader macroeconomic sentiment toward the biotech sector.